These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30659126)

  • 21. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study.
    Lee JY; Lee JH; Seo J; Kang M; Jung EH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
    J Korean Med Sci; 2024 Jun; 39(22):e175. PubMed ID: 38859738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
    Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Mitsiades CS; Rosenblatt J; Mahindra A; Raje N; Munshi N; Anderson KC
    Eur J Haematol; 2012 Jan; 88(1):1-7. PubMed ID: 21991938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.
    Wu EQ; Bensimon AG; Marynchenko M; Namjoshi M; Guo A; Yu AP; Ericson SG; Raje N
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):326-35. PubMed ID: 21700528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis.
    Huang SY; Yoon SS; Shimizu K; Chng WJ; Chang CS; Wong RS; Gao S; Wang Y; Gordon SW; Glennane A; Min CK
    Adv Ther; 2020 Jul; 37(7):3404-3416. PubMed ID: 32524500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.
    Goto D; Khairnar R; Yared JA; Yong C; Romanus D; Onukwugha E; Slejko JF
    Cancer Med; 2020 Jan; 9(2):626-639. PubMed ID: 31801177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
    Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
    Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
    Wang Z; Qiao D; Lu Y; Curtis D; Wen X; Yao Y; Zhao H
    Oncologist; 2015 Apr; 20(4):440-9. PubMed ID: 25732263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
    Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
    Bhowmik D; Hines DM; Intorcia M; Wade RL
    J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective analysis to examine factors associated with mortality in Medicare beneficiaries newly diagnosed with multiple myeloma.
    Yusuf AA; Natwick T; Werther W; Felici D; Mahue M; Bridges KR; Peng Y
    Curr Med Res Opin; 2016 Dec; 32(12):1989-1996. PubMed ID: 27532155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
    Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G
    J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
    Brincker H; Westin J; Abildgaard N; Gimsing P; Turesson I; Hedenus M; Ford J; Kandra A
    Br J Haematol; 1998 May; 101(2):280-6. PubMed ID: 9609523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
    McKay RR; Lin X; Perkins JJ; Heng DY; Simantov R; Choueiri TK
    Eur Urol; 2014 Sep; 66(3):502-9. PubMed ID: 24613250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma.
    Jeon HL; Oh IS; Baek YH; Yang H; Park J; Hong S; Shin JY
    J Bone Miner Metab; 2020 Mar; 38(2):254-263. PubMed ID: 31673791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
    Barlev A; Song X; Ivanov B; Setty V; Chung K
    J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
    Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
    Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma.
    Zhou J; Sweiss K; Han J; Ko NY; Patel PR; Chiu BC; Calip GS
    JAMA Netw Open; 2021 Jul; 4(7):e2118410. PubMed ID: 34313746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.